Adalvo is excited to announce the launch of Solifenacin + Tamsulosin in Europe. Our niche product is a fully bioequivalent version of Vesomni MR Tablets, 6mg/0.4mg, indicated in the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men.
Our product has been developed in collaboration with our strategic partner Adamed Pharma, a Polish research- and patent-based pharmaceutical and biotechnology company with over 30 years of experience, founded on the basis of Polish scientific advances and a patent portfolio. Adamed provides patients with the highest quality medicinal products across 19 therapeutic areas. For more than 20 years, the company also has been conducting its own innovative R&D work. Currently the development of innovative drugs at Adamed is focused on three therapeutic areas: diabetology, oncology and neuropsychiatry.
This effective collaboration has allowed Adalvo to successfully launch this high-value, niche product on Day 1 in all major markets. This success story is a testament to the exceptional collaboration between Adalvo and Adamed in our co-development partnership.
We are thrilled with our successful day-1 launch of this complex fixed dose combination product. Adalvo is in a leading position with this product launch through its top-tier partners. We also want to thank Adamed for the great partnership and looking forward to working successfully together for many years.
Our mission is respond to the key challenges of modern medicine. As a company established and still run by doctors, Adamed has always put patients’ best interests first. That is why we appreciate the cooperation between Adamed and Adalvo, which is based on a deep understanding of patients, their needs and expectations